Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 14;44(1):78.
doi: 10.1007/s10792-024-03015-x.

Review of lipocalin-2-mediated effects in diabetic retinopathy

Yajuan Zhang  1   2   3 , Xiaojun Song  1   2   3 , Tianying Qi  1   2   3 , Xinli Zhou  4   5   6
Affiliations
Review

Review of lipocalin-2-mediated effects in diabetic retinopathy

Yajuan Zhang et al. Int Ophthalmol. .

Abstract

Background: Studies have uncovered LCN2 as a marker of inflammation strongly related to obesity, insulin resistance, and abnormal glucose metabolism in humans, and is involved in vascular diseases, inflammatory diseases, and neurological diseases. In recent years, studies have shown that elevated levels of LCN2 have a strong association with diabetic retinopathy (DR), but the pathogenesis is unknown. Here, we reviewed the relevant literature and compiled the pathogenesis associated with LCN2-induced DR.

Methods: We searched PubMed and Web of Science electronic databases using "lipocalin-2, diabetic retinopathy, retinal degeneration, diabetic microangiopathies, diabetic neuropathy and inflammation" as subject terms.

Results: In diabetic retinal neuropathy, LCN2 causes impaired retinal photoreceptor function and retinal neurons; in retinal microangiopathy, LCN2 induces apoptosis of retinal vascular endothelial cells and promotes angiogenesis; in retinal inflammation, increased secretion of LCN2 recruits inflammatory cells and induces pro-inflammatory cytokines. Moreover, LCN2 has the potential as a biomarker for DR. Recent studies have shown that retinal damage can be attenuated by silencing LCN2, which may be associated with the inhibition of caspase-1-mediated pyroptosis, and LCN2 may be a new target for the treatment of DR.

Conclusions: In conclusion, LCN2, involved in the development of diabetic retinopathy, is a key factor in diabetic retinal microangiopathy, neurodegeneration, and retinal inflammation. LCN2 is likely to be a novel molecular target leading to DR, and a more in-depth study of the pathogenesis of DR caused by LCN2 may provide considerable benefits for clinical research and potential drug development.

Keywords: Diabetic microangiopathies; Diabetic neuropathy; Diabetic retinopathy; Inflammation; Lipocalin-2; Retinal degeneration.

PubMed Disclaimer

References

    1. Olsen TW, Al-Rajhi A, Ambrus A et al (2020) Diabetic retinopathy preferred practice pattern (R). Ophthalmology 127:P66–P145. https://doi.org/10.1016/j.ophtha.2019.09.025 - DOI
    1. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136. https://doi.org/10.1016/S0140-6736(09)62124-3 - DOI - PubMed
    1. Heng LZ, Comyn O, Peto T et al (2013) Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med 30:640–650. https://doi.org/10.1111/dme.12089 - DOI - PubMed
    1. Kollias AN, Ulbig MW (2010) Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int. https://doi.org/10.3238/arztebl.2010.0075 - DOI - PubMed - PMC
    1. Wong TY, Cheung CMG, Larsen M et al (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012. https://doi.org/10.1038/nrdp.2016.12 - DOI - PubMed

LinkOut - more resources